Prothena Corporation plc (NASDAQ:PRTA) — Market Cap & Net Worth
Market Cap & Net Worth: Prothena Corporation plc (PRTA)
Prothena Corporation plc (NASDAQ:PRTA) has a market capitalization of $482.32 Million ($482.32 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12720 globally and #2968 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prothena Corporation plc's stock price $10.64 by its total outstanding shares 53829982 (53.83 Million). Analyse Prothena Corporation plc (PRTA) cash flow conversion to see how efficiently the company converts income to cash.
Prothena Corporation plc Market Cap History: 2015 to 2026
Prothena Corporation plc's market capitalization history from 2015 to 2026. Data shows change from $3.67 Billion to $572.75 Million (-13.49% CAGR).
Index Memberships
Prothena Corporation plc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #327 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1216 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.03% | #184 of 263 |
Weight: Prothena Corporation plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prothena Corporation plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prothena Corporation plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.52x
Prothena Corporation plc's market cap is 5.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.67 Billion | $1.61 Million | -$80.61 Million | 2281.49x | N/A |
| 2016 | $2.65 Billion | $1.05 Million | -$160.11 Million | 2509.85x | N/A |
| 2017 | $2.02 Billion | $27.52 Million | -$153.24 Million | 73.33x | N/A |
| 2018 | $554.45 Million | $955.00K | -$155.65 Million | 580.57x | N/A |
| 2019 | $852.13 Million | $814.00K | -$77.68 Million | 1046.84x | N/A |
| 2020 | $646.50 Million | $853.00K | -$111.14 Million | 757.91x | N/A |
| 2021 | $2.66 Billion | $200.58 Million | $66.97 Million | 13.26x | 39.70x |
| 2022 | $3.24 Billion | $53.91 Million | -$116.95 Million | 60.17x | N/A |
| 2023 | $1.96 Billion | $91.37 Million | -$147.03 Million | 21.41x | N/A |
| 2024 | $745.55 Million | $135.16 Million | -$122.31 Million | 5.52x | N/A |
Competitor Companies of PRTA by Market Capitalization
Companies near Prothena Corporation plc in the global market cap rankings as of May 2, 2026.
Key companies related to Prothena Corporation plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Prothena Corporation plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Prothena Corporation plc's market cap moved from $3.67 Billion to $ 572.75 Million, with a yearly change of -13.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $572.75 Million | +11.41% |
| 2025 | $514.08 Million | -31.05% |
| 2024 | $745.55 Million | -61.89% |
| 2023 | $1.96 Billion | -39.68% |
| 2022 | $3.24 Billion | +21.96% |
| 2021 | $2.66 Billion | +311.32% |
| 2020 | $646.50 Million | -24.13% |
| 2019 | $852.13 Million | +53.69% |
| 2018 | $554.45 Million | -72.53% |
| 2017 | $2.02 Billion | -23.79% |
| 2016 | $2.65 Billion | -27.78% |
| 2015 | $3.67 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Prothena Corporation plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $482.32 Million USD |
| MoneyControl | $482.32 Million USD |
| MarketWatch | $482.32 Million USD |
| marketcap.company | $482.32 Million USD |
| Reuters | $482.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more